Apintyx Inc. will develop its lead compound, NYX-2925, to treat neuropathic pain
linked to diabetic peripheral neuropathy.
NYX-2925 has received Fast
Track designation from the U.S. Food and Drug Administration.
"Our team has evaluated NYX-2925 in multiple models of
neurologic conditions, and we see tremendous potential for it to address the
unmet need in painful diabetic peripheral neuropathy," Aptinyx CMO
Torsten Madsen said. "Patients with this condition struggle to manage
their pain effectively with the therapeutic options currently available. Our
goal is to complete the Phase 1 study and start a Phase 2 study in 2017. We
will also continue to evaluate additional neurologic disorders for which
NYX-2925 and other Aptinyx molecules may have clinical applications."
Apintyx has chosen to move forward with the development of
NYX-2925 due to results from preclinical studies that support the drug’s use
for neuropathic pain. These results will be presented at the
16th World Congress on Pain in Japan.
A Phase 1 trial to assess the safety and patient tolerance
of NYX-2925 are underway using healthy volunteers. The trial is
randomized, double-blind and placebo-controlled.
Apintyx to move forward with development of NYX-2925
Alerts Sign-up